Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 17/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | TACR2 | P21452 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857199 | 0.92 | DRD2 (0.49) | CCR5DRD2SLC6A4CCR2CYP2D6 | |
| SCHEMBL3596577 | 0.91 | DRD2 (0.48) | CCR5DRD2SLC6A4CCR2CYP2D6 | |
| SCHEMBL3589931 | 0.91 | SLC6A4 (0.48) | CCR5DRD2SLC6A4TACR2 | |
| SCHEMBL5451951 | 0.90 | CCR5 (0.58) | CCR5CYP2D6 | |
| SCHEMBL5451946 | 0.90 | CCR5 (0.58) | CCR5CYP2D6 | |
| SCHEMBL3597050 | 0.86 | CCR5 (0.46) | CCR5DRD2SLC6A4TACR2 | |
| SCHEMBL3610524 | 0.86 | CCR5 (0.58) | CCR5DRD2SLC6A4TACR2 | |
| SCHEMBL3602016 | 0.83 | DRD2 (0.55) | DRD2SLC6A4 | |
| SCHEMBL5858616 | 0.83 | DRD2 (0.69) | CCR5DRD2SLC6A4CYP2D6TACR2 | |
| SCHEMBL3597043 | 0.82 | DRD2 (0.49) | DRD2SLC6A4TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989393-B2 | Ccr5 modulators benzimidazoles or benzotriazoles | ASTRAZENECA AB (SE) | 2006-01-24 | — | — | US | disclosed |
| US-20030119869-A1 | Ccr5 modulators benzimidazoles or benzotriazoles | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | disclosed |
| EP-1265870-A1 | NEW CCR5 MODULATORS: BENZIMIDAZOLES OR BENZOTRIAZOLES | AstraZeneca AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001066525-A1 | NEW CCR5 MODULATORS: BENZIMIDAZOLES OR BENZOTRIAZOLES | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119869-A1 | Ccr5 modulators benzimidazoles or benzotriazoles | CCR5, CCR2, CXCR4 | CCR5 1/4885DRD2 1216/4885SLC6A4 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.